<?xml version="1.0" encoding="UTF-8"?>
<Label drug="syprine" track="TAC2017_ADR">
  <Text>
    <Section name="adverse reactions" id="S1">    ADVERSE REACTIONS

  Clinical experience with SYPRINE has been limited. The following adverse reactions have been reported in a clinical study in patients with Wilson's disease who were on therapy with trientine hydrochloride: iron deficiency, systemic lupus erythematosus (see  CLINICAL PHARMACOLOGY  ). In addition, the following adverse reactions have been reported in marketed use: dystonia, muscular spasm, myasthenia gravis.



 SYPRINE is not indicated for treatment of biliary cirrhosis, but in one study of 4 patients treated with trientine hydrochloride for primary biliary cirrhosis, the following adverse reactions were reported: heartburn; epigastric pain and tenderness; thickening, fissuring and flaking of the skin; hypochromic microcytic anemia; acute gastritis; aphthoid ulcers; abdominal pain; melena; anorexia; malaise; cramps; muscle pain; weakness; rhabdomyolysis. A causal relationship of these reactions to drug therapy could not be rejected or established.
</Section>
  </Text>
  <Mentions />
  <Relations />
  <Reactions />
</Label>
